In a recent retrospective study, top myeloma specialists collaborated to learn if any specific gene signature indicates whether a patient's myeloma will or won't respond to a standard drug class - the immunomodulators (iMiDs). This is key because iMiDs are a staple myeloma therapy and are many times used for maintenance. There are many patients who would like to know if the drug will have its intended effect as part of their treatment combination.
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.